NasdaqGM - Nasdaq Real Time Price USD
XOMA Royalty Corporation (XOMA)
As of 11:10 AM EDT. Market Open.
Research Analysis
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | -0.44 | -0.39 | -0.12 | -0.59 |
| Low Estimate | -0.66 | -0.6 | -0.77 | -1.31 |
| High Estimate | -0.32 | -0.21 | 0.25 | 0.15 |
| Year Ago EPS | -0.6 | -1.87 | -4.04 | -0.12 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 3 | 3 | 3 | 3 |
| Avg. Estimate | 6.49M | 6.89M | 25.96M | 33.7M |
| Low Estimate | 5.66M | 5.94M | 24.17M | 32.6M |
| High Estimate | 7.62M | 7.6M | 27.3M | 35.3M |
| Year Ago Sales | 830k | 1.83M | 4.76M | 25.96M |
| Sales Growth (year/est) | 681.90% | 275.90% | 445.60% | 29.80% |
Earnings History
| CURRENCY IN USD | 9/30/2023 | 12/31/2023 | 3/31/2024 | 6/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.48 | -0.36 | -0.81 | -0.27 |
| EPS Actual | -0.6 | -1.87 | -0.86 | 0.84 |
| Difference | -0.12 | -1.51 | -0.05 | 1.11 |
| Surprise % | -25.00% | -419.40% | -6.20% | 411.10% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.44 | -0.39 | -0.12 | -0.59 |
| 7 Days Ago | -0.44 | -0.39 | -0.12 | -0.59 |
| 30 Days Ago | -0.44 | -0.39 | -0.12 | -0.59 |
| 60 Days Ago | -0.44 | -0.39 | -0.12 | -0.59 |
| 90 Days Ago | -0.61 | -0.47 | -1.89 | -1.32 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Sep 2024) | Next Qtr. (Dec 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | XOMA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 26.70% | -- | -- | 5.10% |
| Next Qtr. | 79.10% | -- | -- | 11.80% |
| Current Year | 97.00% | -- | -- | 2.10% |
| Next Year | -391.70% | -- | -- | 12.30% |
| Next 5 Years (per annum) | 19.00% | -- | -- | 11.68% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Upgrades & Downgrades
| Reiterates | HC Wainwright & Co.: Buy to Buy | 10/23/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/20/2024 |
| Maintains | HC Wainwright & Co.: Buy to Buy | 8/15/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 7/9/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/31/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 5/1/2024 |
Related Tickers
AGIO Agios Pharmaceuticals, Inc.
44.41
-0.05%
ORKA Oruka Therapeutics, Inc.
28.19
+0.66%
LGND Ligand Pharmaceuticals Incorporated
109.40
+3.50%
XNCR Xencor, Inc.
21.08
+0.33%
IDYA IDEAYA Biosciences, Inc.
28.03
-0.43%
TYRA Tyra Biosciences, Inc.
16.22
-2.76%
PRTA Prothena Corporation plc
16.99
-0.06%
ATYR aTyr Pharma, Inc.
3.1000
-0.64%
RGNX REGENXBIO Inc.
8.64
+0.58%
ANAB AnaptysBio, Inc.
21.75
+0.53%